[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delayed-wound-healing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delayed-wound-healing":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,85,126,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631531","investigating-the-impact-of-cold-atmospheric-plasma-treatment-on-wound-healing-at-cannulation-sites-in-patients-following-extracorporeal-life-support-100631531",false,"NCT07501897","Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Following Extracorporeal Life Support","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Receiving extracorporeal life support (ECLS)\n* Presence of cannulation site wound requiring wound care\n\nExclusion Criteria:\n\n* Pre-existing severe dermatological conditions at the cannulation site\n* Severe coagulopathy precluding local intervention\n* Concurrent receipt of other experimental wound treatments\n* Life expectancy \\\u003C 48 hours","ALL","18 Years",{"count":18,"type":19},65,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study aims to evaluate a new wound treatment called cold atmospheric plasma (CAP) for patients receiving extracorporeal life support (ECLS). Patients on extracorporeal life support (ECLS) often develop wounds at the sites where tubes are inserted, and these wounds can be difficult to heal and prone to infection.\n\ncold atmospheric plasma (CAP) is a gentle, non-heat treatment that can kill bacteria, reduce inflammation, and promote wound healing. In this study, patients will be randomly assigned to receive either standard wound care alone or standard care plus cold atmospheric plasma (CAP) treatment.\n\nResearchers will compare both groups to see whether cold atmospheric plasma (CAP) can reduce infection, improve healing speed, and decrease the need for additional procedures. The study will also monitor safety to ensure the treatment is well tolerated.\n\nThe goal is to find a more effective and safe way to improve wound healing in critically ill patients.",[25,26,27,28,29],"ExtraCorporeal Life Support (ECLS)","Wound Infection","Surgical Site Infection","Delayed Wound Healing","Biofilm-Associated Infection",[31,32],"Extracorporeal Life Support","cold atmospheric plasma","RECRUITING","2026-03-25",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":37},"2026-03-12",{"date":41,"type":19},"2026-12-31",{"name":43,"class":44},"National Taiwan University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":70,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100562499","prevention-of-edema-after-coronary-artery-bypass-graft-by-customized-pressure-guided-elastic-bandages-100562499","NCT06603961","Prevention of Edema After Coronary Artery Bypass Graft by Customized Pressure-guided Elastic Bandages","Efficacy of Customized Pressure-Guided Elastic Bandages in Preventing Postoperative Edema and Complications in Coronary Artery Bypass Graft (CABG) Patients: A Comparative Study of Compression Therapy and Standard Post-CABG Care.","PEACCE","Inclusion Criteria:\n\n1. All patients scheduled for elective coronary artery bypass grafting (CABG) surgery with saphenous vein harvesting from the leg at Siriraj Hospital.\n2. Patients aged 18 years and older undergoing CABG surgery with saphenous vein harvesting from the leg at Siriraj Hospital, who willingly consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with an Ankle-brachial pressure index (ABI) \\\u003C 0.8\n2. Patients with severe leg swelling (pitting edema of grade 3 or higher) or with pre-existing or post-operative heart failure that remains uncontrolled despite diuretic therapy.\n3. Patients with occlusive peripheral arterial disease (PAD) or chronic venous insufficiency (CEAP 2s), characterized by significant venous stasis, leg pain, varicose veins, or lymphadenopathy.",true,{"count":56,"type":19},106,[22],"The study aimed to assess the efficacy of customized pressure-guided elastic bandages (CPG-EB) in preventing postoperative edema and complications in Coronary Artery Bypass Graft (CABG) patients. While compression therapy, like compressive stockings, has benefits in preventing edema, concerns about affordability persist. CPG-EB provides optimal sub-bandage pressure, proven effective in venous leg ulcers. Implementing CPG-EB post-CABG could enhance venous blood flow, reducing complications and improving outcomes. Patients were divided into two groups: one with CPG-EB and the other standard post-CABG care. Data collected at 1, 2, and 6 weeks post-surgery assessed swelling and wound complications. Comparative analysis used standardized criteria.",[60,61,62,63,64,65,66,67,28,68,69],"Limb Edema","Surgical Site Infections","Leg Swelling","Compression Bandages","Coronary Artery Bypass Graft","CABG","Saphenectomy","Saphenous Vein","Post Operative Complications","Post Operative Surgical Site Infection",[71,72,73,65,74],"compression bandages","compression therapy","customized pressure-guided elastic bandages","coronary arterial bypass graft","2026-02-06",{"date":77,"type":37},"2026-02-09",{"date":79,"type":37},"2025-01-19",{"date":81,"type":19},"2026-05-31",{"name":83,"class":44},"Siriraj Hospital",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":45},"100617994","patients-referred-to-the-chronic-pain-unit-for-palliative-treatment-with-ozone-therapy-between-2026-and-2029-100617994","NCT07325851","Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.","Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. Prospective Study EPOOzo-2.","EPOOzo-2","Inclusion Criteria:\n\n* 1\\. Adults ≥ 18 years old.\n* 2\\. Patients referred to the Chronic Pain Unit of the Dr. Negrín University Hospital for symptomatic\u002Fpalliative treatment with ozone therapy because conventional treatment does not exist, has failed, has offered insufficient results, or is associated with high risk\u002Fmorbidity.\n* 3\\. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.\n* 4\\. Patients have no contraindications for ozone treatment.\n* 5\\. Patients must sign the specific Informed Consent for this study and for the ozone treatment.\n\nExclusion Criteria:\n\n* 1\\. Age \\\u003C 18 years old.\n* 2\\. Psychiatric illness or social situations that would limit compliance with study requirements.\n\nContraindication or disability to attend scheduled treatments.\n\n* 3\\. Contraindication or disability to attend scheduled treatments.\n* 4\\. Uncontrolled clinical conditions (e.g., severe heart failure, massive hemorrhage, status epilepticus).\n* 5\\. Life expectancy \\\u003C 6 months.\n* 6\\. Known allergy to ozone.\n* 7\\. Hemochromatosis (for systemic ozone treatment).\n* 8\\. Pregnancy (for systemic ozone treatment).\n* 9\\. Significant Glucose-6-Phosphate Dehydrogenase deficiency (Favism) (for systemic ozone treatment).\n* 10\\. Patients who do not meet the inclusion criteria.",{"count":94,"type":19},120,"40 Weeks","OBSERVATIONAL","The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.",[99,100,101,28,102],"Chemotherapy-Induced Peripheral Neuropathy","Radiation Toxicity","Chronic Pain","Refractory Symptoms",[104,105,106,107,108,109,110,111,112,113,114,115],"Ozone Therapy","Health-related quality of life","Chemotherapy-induced Peripheral Neuropathy","Radiation-induced toxicity","Hyperspectral imaging","Infrared imaging","Heart Rate Variability","Sudoscan","Vibrometry","Oxidative stress","Gut Microbiota","Anxiety and Depression","NOT_YET_RECRUITING","2025-12-23",{"date":119,"type":37},"2026-01-08",{"date":121,"type":19},"2026-01-14",{"date":123,"type":19},"2030-06-30",{"name":125,"class":44},"Bernardino Clavo, MD, PhD",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":96,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100471350","patients-referred-to-the-chronic-pain-unit-for-palliative-treatment-with-ozone-therapy-between-2022-and-2025-100471350","NCT05417737","Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025","Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025. (EPOOzo)","EPOOzo","Inclusion Criteria:\n\n1. Adults \\> = 18 years old.\n2. Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín for symptomatic\u002Fpalliative treatment with ozone therapy because conventional treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.\n3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.\n4. Patients have no contraindications for ozone treatment.\n5. Patients have signed and dated the informed consent for the compassionated ozone treatment and the specific informed consent for this study\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years old.\n2. Psychiatric illness or social situations that would limit compliance with study requirements.\n3. Those who are incapable to fill in the scales used to measure variables.\n4. Hemodynamically or clinically unstable patients or uncontrolled severe illness.\n5. Uncontrolled cancer disease requiring chemotherapy treatment.\n6. Life expectancy \\\u003C 6 months\n7. Contraindication or disability or to attend scheduled treatments.\n8. Known allergy to ozone.\n9. Pregnancy at the time of enrollment (for systemic ozone therapy). 10 Hemochromatosis (for systemic ozone therapy).\n\n11\\. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy).\n\n12\\. Patients who do not meet all the inclusion criteria",{"count":135,"type":19},105,"28 Weeks","The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025",[100,139,106,28,101,140],"Chemotherapeutic Toxicity","Refractory Pain",[106,107,142,143,144,105,115,145,146],"Cancer-treatment side effects","Delayed wound healing","Chronic pain","Ozone therapy","Refractory pain","2025-08-25",{"date":149,"type":37},"2025-09-02",{"date":151,"type":37},"2022-06-15",{"date":153,"type":19},"2026-06-30",{"name":125,"class":44},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":20,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100569759","rada16-on-mastoid-cavity-epithelialization-100569759","NCT06698419","RADA16 on Mastoid Cavity Epithelialization","A Prospective Study: The Effect of RADA16 on Mastoid Cavity Epithelialization After Canal Wall Down Mastoidectomy","Inclusion Criteria:\n\n* English-speaking adults over the age of 18 years who require a canal wall down mastoidectomy for any reason including cholesteatoma, chronic suppurative middle ear disease, and neoplasm.\n* Participants with history of canal wall up mastoidectomy who now require canal wall down mastoidectomy for any reason.\n\nExclusion Criteria:\n\n* History of chronic immunodeficiency and autoimmune disease\n* History of head and neck radiation\n* Active tobacco use\n* History of coronary artery disease\n* History of peripheral vascular disease\n* History of diabetes mellitus\n* Known allergy to RADA16 gel or its components\n* Vulnerable populations including children, neonates, pregnant women, prisoners, institutionalized individuals, and other individuals who are unable to provide informed consent",{"count":163,"type":19},14,[22],"The goal of this clinical trial is to see if the application of RADA16 gel can expedite and improve the healing process in participants after canal wall down mastoidectomy. The main questions are:\n\n* Does application of RADA16 in the mastoid cavity after canal wall down mastoidectomy lead to faster healing (i.e. epithelialization)?\n* Is application of RADA16 in the mastoid cavity after canal wall down mastoidectomy associated with a decreased need for medications after surgery (i.e. antibiotics, steroids), less frequent in-office debridements, and less postoperative appointments?\n\nResearchers will compare the healing outcomes in participants treated with RADA16 gel to those in a control group who do not receive the treatment.\n\nParticipants will:\n\n* Undergo canal wall down mastoidectomy as recommended regardless of participation in the clinical trial\n* Follow-up postoperatively for clinical assessment at 1 month, 2 months, 3 months, 6 months, 1 year, 18 months, and 2 years. Participants may follow-up more frequently as needed.",[28],[168,169,170,171,172],"Mastoidectomy","Healing","Biologic","Mastoid cavity","Mastoid cavity disease","2024-11-18",{"date":175,"type":37},"2024-11-21",{"date":177,"type":19},"2025-01-01",{"date":179,"type":19},"2027-01-01",{"name":181,"class":44},"University of Florida"]